Shankara Medicines Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 16-11-2024
- Company Age 27 Year, 7 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.53 Cr
as on 16-11-2024
- Satisfied Charges ₹ 12.90 Cr
as on 16-11-2024
- Revenue 7.54%
(FY 2023)
- Profit -70.86%
(FY 2023)
- Ebitda -19.54%
(FY 2023)
- Net Worth 0.22%
(FY 2023)
- Total Assets -10.63%
(FY 2023)
About Shankara Medicines
The Corporate was formerly known as Vasantha Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹5.53 Cr. The company has closed loans amounting to ₹12.90 Cr, as per Ministry of Corporate Affairs (MCA) records.
Maruthai Periyasamy and Manjula Maruthai serve as directors at the Company.
- CIN/LLPIN
U24231TN1997PTC039609
- Company No.
039609
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Shankara Medicines?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Maruthai Periyasamy  | Managing Director | 10-Oct-2007 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manjula Maruthai | Director | 10-Oct-2007 | Current |
Financial Performance of Shankara Medicines.
Shankara Medicines Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.54% increase. The company also saw a substantial fall in profitability, with a 70.86% decrease in profit. The company's net worth moved up by a moderate rise of 0.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shankara Medicines?
In 2023, Shankara Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Dec 2017 | ₹5.53 Cr | Open |
Kotak Mahindra Bank Limited Creation Date: 21 Aug 2015 | ₹4.75 Cr | Satisfied |
Standard Chartered Bank Creation Date: 26 Dec 2007 | ₹3.15 Cr | Satisfied |
How Many Employees Work at Shankara Medicines?
Unlock and access historical data on people associated with Shankara Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shankara Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shankara Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
